93288-20-1

Basic information

• Product Name: 2-Pyrrolidinone, 5-[[(methylsulfonyl)oxy]methyl]-, (S)-
• CAS NO: 93288-20-1
• Molecular Formula: C6H11NO4S
• Molecular Weight: 193.224
• Mol File: 93288-20-1.mol

Chemical Properties

• CAS DataBase Reference: 2-Pyrrolidinone, 5-[[(methylsulfonyl)oxy]methyl]-, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyrrolidinone, 5-[[(methylsulfonyl)oxy]methyl]-, (S)-(93288-20-1)
• EPA Substance Registry System: 2-Pyrrolidinone, 5-[[(methylsulfonyl)oxy]methyl]-, (S)-(93288-20-1)

Safety Data

• Hazardous Substances Data: 93288-20-1(Hazardous Substances Data)

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 17342-08-4 (S)-Pyroglutaminol 

Downstream Products

• 72479-06-2 2-[(2S)-5-oxopyrrolidin-2-yl]acetonitrile 
• 1269473-24-6 (S)-5-((2-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-pyrrol-1-yl)methyl)-2-mesityl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-32-6 (S)-5-((2-(3,5-bis(trifluoromethyl)phenyl)-1H-pyrrol-1-yl)methyl)-2-mesityl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-27-9 (S)-5-((2-(3,5-di-tert-butylphenyl)-5-methyl-1H-pyrrol-1-yl)methyl)-2-mesityl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-19-9 (S)-5-((2-(3,5-dimethylphenyl)-5-methyl-1H-pyrrol-1-yl)methyl)-2-mesityl-6,7-dihydro-5Hpyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-20-2 (S)-2-mesityl-5-((2-(4-methoxyphenyl)-5-methyl-1H-pyrrol-1-yl)methyl)-6,7-dihydro-5Hpyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-18-8 (S)-2-mesityl-5-((2-methyl-5-phenyl-1H-pyrrol-1-yl)methyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-31-5 (S)-2-mesityl-5-((2-(4-methoxyphenyl)-1H-pyrrol-1-yl)methyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-33-7 (S)-2-mesityl-5-((3-phenylthioureido)methyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium 
• 1269473-30-4 (S)-2-mesityl-5-((2-phenyl-1H-pyrrol-1-yl)methyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-29-1 (S)-2-mesityl-5-((2-methyl-1H-pyrrol-1-yl)methyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-11-1 (S)-5-(azidomethyl)-2-mesityl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 
• 1269473-13-3 C₁₅H₂₀N₃O⁽¹⁺⁾*Cl^(1-) 
• 1269473-12-2 (S)-5-(aminomethyl)-2-mesityl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium chloride 

Relevant articles and documents

PD-1/PD-L1 INHIBITORS

Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed Formula (I)

Zr-mediated synthesis of chiral cyclic imines and their application in Betti reactions

[Figure not available: see fulltext.] A novel synthetic strategy has been outlined to assemble enantiomerically pure Betti bases with unprecedented structures. This involves the Zr-mediated reduction of pyrrolidin-2-ones to cyclic imines and their subsequent reaction with phenolic derivatives.

AGENTS FOR TREATING PAIN AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Straightforward synthesis of non-natural l-chalcogen and l-diselenide N-Boc-protected-γ-amino acid derivatives

The synthesis of new chiral seleno-, telluro-, and thio-N-Boc-γ-amino acids is described herein. These new compounds were prepared through a simple and short synthetic route, from the inexpensive and commercially-available amino acid l-glutamic acid. The products, with a highly modular character, were obtained in good to excellent yields, via hydrolysis of chalcogen pyroglutamic derivatives with overall retention of the l-glutamic acid stereochemistry. Also, an l-diselenide-N-Boc-γ-amino acid was prepared in good yield. This new synthetic route represents an efficient method for preparing new l-chalcogen- and l-diselenide-γ-amino acids with biological potential.

Late-stage diversification of chiral N-heterocyclic-carbene precatalysts for enantioselective homoenolate additions

A library of chiral triazolium salts has been prepared by late-state diversification of a triazolium amine salt. By utilizing a primary amine as a functional handle, a single triazolium salt can be transformed into a variety of chiral N-heterocyclic carbene precatalysts. This approach makes the preparation of chiral N-heterocyclic carbenes possible by a single-step modification of a triazolium salt, rather than the usual need for multistep organic synthesis and challenging heterocycle formation for each member of a catalyst library. We have screened these catalysts for control of diastereo- and enantioselectivity in a γ-lactam-forming reaction between α,β-unsaturated aldehydes and cyclic ketimines. Saving the best for last: Enantioselective homoenolate additions have been hindered by the challenge of synthesizing N-mesityl-substituted azolium salts. A library of pyrrole-functionalized chiral triazolium salts was prepared by direct modification of the preformed azolium core. Copyright

Synthesis of chiral bifunctional (Thio)urea n-heterocyclic carbenes

The rapid and modular synthesis of the first bifunctional N-heterocyclic carbenes bearing a (thio)urea moiety as H-bond donor group was reported. Different analogues could be accessed in seven steps from cheap (S)-pyroglutamic acid in good overall yields (14-30%). The synthesized carbenes were active catalysts in the benzoin reaction. Georg Thieme Verlag Stuttgart - New York.

Nitrogen-containing bicyclic compounds active on chronic pain conditions

The invention refers to compounds of general formula (I) wherein the R groups are, independently, H, C1-6alkyl, aryl, CF3; Y is CH2, C=O; X is bond, C=O, SO2, or C=N-CN; m is 0, 1; n is 0, 1; A is a heterocycle, or a phenyl group optionally substituted. The compounds are active on chronic pain conditions of different origin; they can be administered alone or with other drugs. Most of these compounds are new. The invention include a process to prepare said compounds, and pharmaceutical compositions suitable for their administration to a patient.

New chiral diamide ligands: synthesis and application in allylic alkylation

A new family of chiral diamide ligands has been designed and synthesised. These ligands have been successfully applied to an asymmetric allylic substitution reaction. A palladium complex of one of the diamide ligands achieved enantioselectivities of up to 93% in the allylic alkylation of 1,3-diphenyl-3-acetoxyprop-1-ene.

Diastereoselective synthesis of enantiopure differentially protected cis-4,5-diaminopiperidin-2-one through intramolecular transamidation

The diastereoselective synthesis of enantiopure differentially protected cis-4,5-diaminopiperidin-2-one was achieved by means of conjugate addition of ammonia to an unsaturated γ-lactam and transamidation reaction with ring expansion as the main steps.

Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor

4-Amino-5-hexenoic acid is prepared by: (a) reacting 5-oxo-2-pyrrolidine-acetonitrile with hydrogen and dimethylamine in the presence of a palladium catalyst to form N,N-dimethyl-2-[5'-oxo-2'-pyrrolidine]ethylamine; (b) oxidizing N,N-dimethyl-2-[5'-oxo-2'-pyrrolidine]-ethylamine to produce the corresponding N-oxide derivative; (c) pyrolysis of the N-oxide derivative to form 5-vinyl-2-pyrrolidinone; (d) optionally, separating N,N-dimethyl-2-[5'-oxo-2'-pyrrolidine]ethylamine by-product from the 5-vinyl-2-pyrrolidinone product; and (e) hydrolyzing 5-vinyl-2-pyrrolidinone to form 4-amino-5-hexenoic acid.